Portrazza, also known as necitumumab, is a medication used in the treatment of advanced non-small cell lung cancer (NSCLC). It is classified as a monoclonal antibody that works by targeting and blocking a specific protein called epidermal growth factor receptor (EGFR), which is often overexpressed in NSCLC tumors.

Portrazza is typically used in combination with other chemotherapy medications, such as gemcitabine and cisplatin, for patients with metastatic NSCLC that has not responded to other treatments. It is administered intravenously and is usually given once a week.

As with any medication, Portrazza can cause side effects. Common side effects may include skin rash, diarrhea, fatigue, and low magnesium levels. More serious side effects, such as infusion reactions and blood clots, are less common but can occur. It is important for patients to discuss any concerns or side effects with their healthcare provider.

It is important to note that Portrazza is not suitable for everyone, and patients with certain medical conditions or allergies may not be able to take this medication. It is crucial for patients to have a thorough discussion with their healthcare provider about their medical history and any other medications they are taking before starting treatment with Portrazza.

Overall, Portrazza can be an effective treatment option for patients with advanced NSCLC when used in combination with other chemotherapy medications. It is important for patients to work closely with their healthcare team to monitor for any potential side effects and to ensure the best possible outcome.